SCHEMBL22374264

SCHEMBL22374264

CC(C)(S)c1ccc(OCC2CC2)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.42
HTR2C P28335 5/20 0.42
HTR2B P41595 4/20 0.42
HTR2A P28223 3/20 0.42
TLR9 Q9NR96 2/20 0.40
TLR8 Q9NR97 2/20 0.40
TLR7 Q9NYK1 2/20 0.40
BRD4 O60885 1/20 0.37
DUT P33316 2/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
FFAR1 O14842 2/20 0.35
PPARD Q03181 2/20 0.35
FFAR4 Q5NUL3 1/20 0.35
ACACB O00763 1/20 0.35
SLC6A9 P48067 1/20 0.35
CHRNA7 P36544 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20206824 0.88 RIPK1 (0.44) RIPK1HTR2CHTR2BHTR2ATLR9
SCHEMBL22414484 0.84 RIPK1 (0.41) RIPK1HTR2CHTR2BHTR2ATLR9
SCHEMBL20347960 0.82 PARP10 (0.40) RIPK1HTR2CHTR2BHTR2AFFAR1
SCHEMBL20206836 0.82 HTR2A (0.39) RIPK1HTR2CHTR2BHTR2AFFAR1
SCHEMBL21690717 0.82 HTR2A (0.40) RIPK1HTR2CHTR2BHTR2ATLR9
SCHEMBL21536713 0.79 MAOB (0.39) RIPK1HTR2CHTR2BHTR2ADUT
SCHEMBL21778452 0.78 VDR (0.44)
SCHEMBL11962822 0.76 HTR2A (0.43) RIPK1HTR2CHTR2BHTR2ATLR9
SCHEMBL28333031 0.76 HTR2A (0.56) RIPK1HTR2CHTR2BHTR2ATLR9
SCHEMBL20347946 0.76 DUT (0.46) RIPK1HTR2CHTR2BHTR2ADUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200270207-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200270207-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD RIPK1 4031/4885HTR2C 3985/4885HTR2B 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.